PIH43 - Early assessment of a new treatment for adolescent idiopathic scoliosis

I.S. Boomkamp, J. Marjan Hummel, Maarten Joost IJzerman, G.B. Verkerke

Research output: Contribution to journalArticleAcademicpeer-review

39 Downloads (Pure)

Abstract

OBJECTIVES: Adolescent idiopathic scoliosis (AIS) reduces the quality of life. It can lead to back pain, reduced back function and socio-psychological problems. Left untreated it may induce cardio-vascular and pulmonary problems, and even death. Current treatment of severe forms of idiopathic scoliosis are based on fusion of the vertebrae. These treatments restrict back function and growth of the adolescents. This study aims to conduct an early technology assessment of a new non-fusion scoliosis correction system. METHODS: The early assessment of this new treatment is supported by the Analytic Hierarchy Process (AHP), a technique for multi-criteria decision analysis. The AHP quantifies the comparison between the performances of decision alternatives under a finite set of decision criteria. An expert panel composed of six technological engineers and medical specialists compared the expected performance of the new non-fusion treatment to the performance of posterior fusion surgery for patients with severe AIS. They regarded criteria related to the quality of life, complications, user friendliness and costs. RESULTS: The expert panel considered the influence of the treatment on the quality of life to be most important (weight 0.46) followed by complications (0.35), user friendliness (0.11) and costs (0.09). They expected the new non-fusion treatment to particularly have a more positive influence on the quality of life (priority 0.73) than posterior surgery has (priority 0.27). Main disadvantage was considered to be the relative high costs of the new treatment (priority 0.37 versus 0.63). In overall, the new treatment is expected to slightly outperform the current treatment (priority 0.63 versus 0.37). CONCLUSIONS: In the absence of clinical evidence, this method provides a valuable means to systematically predict a new technology’s clinical value. The outcomes provide clear directions for medical industry to improve the future cost-effectiveness of new treatments.
Original languageEnglish
Pages (from-to)298-298
Number of pages1
JournalValue in health
Volume12
Issue number7
DOIs
Publication statusPublished - 2009

Fingerprint

Scoliosis
Quality of Life
Therapeutics
Costs and Cost Analysis
Biomedical Technology Assessment
Decision Support Techniques
Back Pain
Health Care Costs
Cost-Benefit Analysis
Blood Vessels
Industry
Spine
Psychology
Weights and Measures
Lung
Growth

Keywords

  • METIS-260334
  • IR-89606

Cite this

Boomkamp, I.S. ; Hummel, J. Marjan ; IJzerman, Maarten Joost ; Verkerke, G.B. / PIH43 - Early assessment of a new treatment for adolescent idiopathic scoliosis. In: Value in health. 2009 ; Vol. 12, No. 7. pp. 298-298.
@article{3cc05901be0e4ee795f6f9d0a088ab1f,
title = "PIH43 - Early assessment of a new treatment for adolescent idiopathic scoliosis",
abstract = "OBJECTIVES: Adolescent idiopathic scoliosis (AIS) reduces the quality of life. It can lead to back pain, reduced back function and socio-psychological problems. Left untreated it may induce cardio-vascular and pulmonary problems, and even death. Current treatment of severe forms of idiopathic scoliosis are based on fusion of the vertebrae. These treatments restrict back function and growth of the adolescents. This study aims to conduct an early technology assessment of a new non-fusion scoliosis correction system. METHODS: The early assessment of this new treatment is supported by the Analytic Hierarchy Process (AHP), a technique for multi-criteria decision analysis. The AHP quantifies the comparison between the performances of decision alternatives under a finite set of decision criteria. An expert panel composed of six technological engineers and medical specialists compared the expected performance of the new non-fusion treatment to the performance of posterior fusion surgery for patients with severe AIS. They regarded criteria related to the quality of life, complications, user friendliness and costs. RESULTS: The expert panel considered the influence of the treatment on the quality of life to be most important (weight 0.46) followed by complications (0.35), user friendliness (0.11) and costs (0.09). They expected the new non-fusion treatment to particularly have a more positive influence on the quality of life (priority 0.73) than posterior surgery has (priority 0.27). Main disadvantage was considered to be the relative high costs of the new treatment (priority 0.37 versus 0.63). In overall, the new treatment is expected to slightly outperform the current treatment (priority 0.63 versus 0.37). CONCLUSIONS: In the absence of clinical evidence, this method provides a valuable means to systematically predict a new technology’s clinical value. The outcomes provide clear directions for medical industry to improve the future cost-effectiveness of new treatments.",
keywords = "METIS-260334, IR-89606",
author = "I.S. Boomkamp and Hummel, {J. Marjan} and IJzerman, {Maarten Joost} and G.B. Verkerke",
note = "ISPOR 12th Annual European Congress, POSTER SESSION I (PIH43). - 24-27 October 2009, Paris, France",
year = "2009",
doi = "10.1016/S1098-3015(10)74461-2",
language = "English",
volume = "12",
pages = "298--298",
journal = "Value in health",
issn = "1098-3015",
publisher = "Elsevier",
number = "7",

}

PIH43 - Early assessment of a new treatment for adolescent idiopathic scoliosis. / Boomkamp, I.S.; Hummel, J. Marjan; IJzerman, Maarten Joost; Verkerke, G.B.

In: Value in health, Vol. 12, No. 7, 2009, p. 298-298.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - PIH43 - Early assessment of a new treatment for adolescent idiopathic scoliosis

AU - Boomkamp, I.S.

AU - Hummel, J. Marjan

AU - IJzerman, Maarten Joost

AU - Verkerke, G.B.

N1 - ISPOR 12th Annual European Congress, POSTER SESSION I (PIH43). - 24-27 October 2009, Paris, France

PY - 2009

Y1 - 2009

N2 - OBJECTIVES: Adolescent idiopathic scoliosis (AIS) reduces the quality of life. It can lead to back pain, reduced back function and socio-psychological problems. Left untreated it may induce cardio-vascular and pulmonary problems, and even death. Current treatment of severe forms of idiopathic scoliosis are based on fusion of the vertebrae. These treatments restrict back function and growth of the adolescents. This study aims to conduct an early technology assessment of a new non-fusion scoliosis correction system. METHODS: The early assessment of this new treatment is supported by the Analytic Hierarchy Process (AHP), a technique for multi-criteria decision analysis. The AHP quantifies the comparison between the performances of decision alternatives under a finite set of decision criteria. An expert panel composed of six technological engineers and medical specialists compared the expected performance of the new non-fusion treatment to the performance of posterior fusion surgery for patients with severe AIS. They regarded criteria related to the quality of life, complications, user friendliness and costs. RESULTS: The expert panel considered the influence of the treatment on the quality of life to be most important (weight 0.46) followed by complications (0.35), user friendliness (0.11) and costs (0.09). They expected the new non-fusion treatment to particularly have a more positive influence on the quality of life (priority 0.73) than posterior surgery has (priority 0.27). Main disadvantage was considered to be the relative high costs of the new treatment (priority 0.37 versus 0.63). In overall, the new treatment is expected to slightly outperform the current treatment (priority 0.63 versus 0.37). CONCLUSIONS: In the absence of clinical evidence, this method provides a valuable means to systematically predict a new technology’s clinical value. The outcomes provide clear directions for medical industry to improve the future cost-effectiveness of new treatments.

AB - OBJECTIVES: Adolescent idiopathic scoliosis (AIS) reduces the quality of life. It can lead to back pain, reduced back function and socio-psychological problems. Left untreated it may induce cardio-vascular and pulmonary problems, and even death. Current treatment of severe forms of idiopathic scoliosis are based on fusion of the vertebrae. These treatments restrict back function and growth of the adolescents. This study aims to conduct an early technology assessment of a new non-fusion scoliosis correction system. METHODS: The early assessment of this new treatment is supported by the Analytic Hierarchy Process (AHP), a technique for multi-criteria decision analysis. The AHP quantifies the comparison between the performances of decision alternatives under a finite set of decision criteria. An expert panel composed of six technological engineers and medical specialists compared the expected performance of the new non-fusion treatment to the performance of posterior fusion surgery for patients with severe AIS. They regarded criteria related to the quality of life, complications, user friendliness and costs. RESULTS: The expert panel considered the influence of the treatment on the quality of life to be most important (weight 0.46) followed by complications (0.35), user friendliness (0.11) and costs (0.09). They expected the new non-fusion treatment to particularly have a more positive influence on the quality of life (priority 0.73) than posterior surgery has (priority 0.27). Main disadvantage was considered to be the relative high costs of the new treatment (priority 0.37 versus 0.63). In overall, the new treatment is expected to slightly outperform the current treatment (priority 0.63 versus 0.37). CONCLUSIONS: In the absence of clinical evidence, this method provides a valuable means to systematically predict a new technology’s clinical value. The outcomes provide clear directions for medical industry to improve the future cost-effectiveness of new treatments.

KW - METIS-260334

KW - IR-89606

U2 - 10.1016/S1098-3015(10)74461-2

DO - 10.1016/S1098-3015(10)74461-2

M3 - Article

VL - 12

SP - 298

EP - 298

JO - Value in health

JF - Value in health

SN - 1098-3015

IS - 7

ER -